keyword
MENU ▼
Read by QxMD icon Read
search

Azd2281

keyword
https://www.readbyqxmd.com/read/27884198/use-of-poly-adp-ribose-polymerase-parp-inhibitors-in-cancer-cells-bearing-ddr-defects-the-rationale-for-their-inclusion-in-the-clinic
#1
REVIEW
Aniello Cerrato, Francesco Morra, Angela Celetti
BACKGROUND: DNA damage response (DDR) defects imply genomic instability and favor tumor progression but make the cells vulnerable to the pharmacological inhibition of the DNA repairing enzymes. Targeting cellular proteins like PARPs, which cooperate and complement molecular defects of the DDR process, induces a specific lethality in DDR defective cancer cells and represents an anti-cancer strategy. Normal cells can tolerate the DNA damage generated by PARP inhibition because of an efficient homologous recombination mechanism (HR); in contrast, cancer cells with a deficient HR are unable to manage the DSBs and appear especially sensitive to the PARP inhibitors (PARPi) effects...
November 24, 2016: Journal of Experimental & Clinical Cancer Research: CR
https://www.readbyqxmd.com/read/27642590/predictors-and-modulators-of-synthetic-lethality-an-update-on-parp-inhibitors-and-personalized-medicine
#2
REVIEW
Stephen Murata, Catherine Zhang, Nathan Finch, Kevin Zhang, Loredana Campo, Eun-Kyoung Breuer
Poly(ADP-ribose) polymerase (PARP) inhibitors have proven to be successful agents in inducing synthetic lethality in several malignancies. Several PARP inhibitors have reached clinical trial testing for treatment in different cancers, and, recently, Olaparib (AZD2281) has gained both United States Food and Drug Administration (USFDA) and the European Commission (EC) approval for use in BRCA-mutated advanced ovarian cancer treatment. The need to identify biomarkers, their interactions in DNA damage repair pathways, and their potential utility in identifying patients who are candidates for PARP inhibitor treatment is well recognized...
2016: BioMed Research International
https://www.readbyqxmd.com/read/27425251/radiosensitization-by-parp-inhibition-to-proton-beam-irradiation-in%C3%A2-cancer-cells
#3
Takahisa Hirai, Soichiro Saito, Hiroaki Fujimori, Keiichiro Matsushita, Teiji Nishio, Ryuichi Okayasu, Mitsuko Masutani
The poly(ADP-ribose) polymerase (PARP)-1 regulates DNA damage responses and promotes base excision repair. PARP inhibitors have been shown to enhance the cytotoxicity of ionizing radiation in various cancer cells and animal models. We have demonstrated that the PARP inhibitor (PARPi) AZD2281 is also an effective radiosensitizer for carbon-ion radiation; thus, we speculated that the PARPi could be applied to a wide therapeutic range of linear energy transfer (LET) radiation as a radiosensitizer. Institutes for biological experiments using proton beam are limited worldwide...
September 9, 2016: Biochemical and Biophysical Research Communications
https://www.readbyqxmd.com/read/27353471/synovial-sarcoma-cell-lines-showed-reduced-dna-repair-activity-and-sensitivity-to-a-parp-inhibitor
#4
Hiroyuki Yamasaki, Mamiko Miyamoto, Yuki Yamamoto, Tadashi Kondo, Toshiki Watanabe, Tsutomu Ohta
Synovial sarcoma is a soft-tissue sarcoma and a rare type of cancer. Unfortunately, effective chemotherapies for synovial sarcomas have not been established. In this report, we show that synovial sarcoma cell lines have reduced repair activity for DNA damage induced by ionizing radiation (IR) and a topoisomerase II inhibitor (etoposide). We also observed reduced recruitment of RAD51 homologue (S. cerevisiae; RAD51) at sites of double-strand breaks (DSBs) in synovial sarcoma cell lines that had been exposed to IR...
August 2016: Genes to Cells: Devoted to Molecular & Cellular Mechanisms
https://www.readbyqxmd.com/read/26975633/apr-246-prima-1-met-strongly-synergizes-with-azd2281-olaparib-induced-parp-inhibition-to-induce-apoptosis-in-non-small-cell-lung-cancer-cell-lines
#5
Christophe Deben, Filip Lardon, An Wouters, Ken Op de Beeck, Jolien Van den Bossche, Julie Jacobs, Nele Van Der Steen, Marc Peeters, Christian Rolfo, Vanessa Deschoolmeester, Patrick Pauwels
APR-246 (PRIMA-1(Met)) is able to bind mutant p53 and restore its normal conformation and function. The compound has also been shown to increase intracellular ROS levels. Importantly, the poly-[ADP-ribose] polymerase-1 (PARP-1) enzyme plays an important role in the repair of ROS-induced DNA damage. We hypothesize that by blocking this repair with the PARP-inhibitor AZD2281 (olaparib), DNA damage would accumulate in the cell leading to massive apoptosis. We observed that APR-246 synergistically enhanced the cytotoxic response of olaparib in TP53 mutant non-small cell lung cancer cell lines, resulting in a strong apoptotic response...
June 1, 2016: Cancer Letters
https://www.readbyqxmd.com/read/26927065/synergetic-effects-of-parp-inhibitor-azd2281-and-cisplatin-in-oral-squamous-cell-carcinoma-in-vitro-and-in-vivo
#6
Masaaki Yasukawa, Hisako Fujihara, Hiroaki Fujimori, Koji Kawaguchi, Hiroyuki Yamada, Ryoko Nakayama, Nanami Yamamoto, Yuta Kishi, Yoshiki Hamada, Mitsuko Masutani
Cisplatin is a commonly used chemotherapeutic drug for treatment of oral carcinoma, and combinatorial effects are expected to exert greater therapeutic efficacy compared with monotherapy. Poly(ADP-ribosyl)ation is reported to be involved in a variety of cellular processes, such as DNA repair, cell death, telomere regulation, and genomic stability. Based on these properties, poly(ADP-ribose) polymerase (PARP) inhibitors are used for treatment of cancers, such as BRCA1/2 mutated breast and ovarian cancers, or certain solid cancers in combination with anti-cancer drugs...
2016: International Journal of Molecular Sciences
https://www.readbyqxmd.com/read/26899229/cediranib-a-pan-vegfr-inhibitor-and-olaparib-a-parp-inhibitor-in-combination-therapy-for-high-grade-serous-ovarian-cancer
#7
S Percy Ivy, Joyce F Liu, Jung-Min Lee, Ursula A Matulonis, Elise C Kohn
INTRODUCTION: An estimated 22,000 women are diagnosed annually with ovarian cancer in the United States. Initially chemo-sensitive, recurrent disease ultimately becomes chemoresistant and may kill ~14,000 women annually. Molecularly targeted therapy with cediranib (AZD2171), a vascular endothelial growth factor receptor (VEGFR)-1, 2, and 3 signaling blocker, and olaparib (AZD2281), a poly(adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitor, administered orally in combination has shown anti-tumor activity in the treatment of high grade serous ovarian cancer (HGSOC)...
2016: Expert Opinion on Investigational Drugs
https://www.readbyqxmd.com/read/26713604/loss-of-ctip-disturbs-homologous-recombination-repair-and-sensitizes-breast-cancer-cells-to-parp-inhibitors
#8
Junhui Wang, Qianshan Ding, Hiroaki Fujimori, Akira Motegi, Yoshio Miki, Mitsuko Masutani
Breast cancer is one of the leading causes of death worldwide, and therefore, new and improved approaches for the treatment of breast cancer are desperately needed. CtIP (RBBP8) is a multifunctional protein that is involved in various cellular functions, including transcription, DNA replication, DNA repair and the G1 and G2 cell cycle checkpoints. CtIP plays an important role in homologous recombination repair by interacting with tumor suppressor protein BRCA1. Here, we analyzed the expression profile of CtIP by data mining using published microarray data sets...
February 16, 2016: Oncotarget
https://www.readbyqxmd.com/read/26650448/poly-adp-ribose-polymerase-inhibition-a-potential-treatment-of-malignant-peripheral-nerve-sheath-tumor
#9
Christine M Kivlin, Kelsey L Watson, Ghadah A Al Sannaa, Roman Belousov, Davis R Ingram, Kai-Lieh Huang, Caitlin D May, Svetlana Bolshakov, Sharon M Landers, Azad Abul Kalam, John M Slopis, Ian E McCutcheon, Raphael E Pollock, Dina Lev, Alexander J Lazar, Keila E Torres
Poly (ADP) ribose polymerase (PARP) inhibitors, first evaluated nearly a decade ago, are primarily used in malignancies with known defects in DNA repair genes, such as alterations in breast cancer, early onset 1/2 (BRCA1/2). While no specific mutations in BRCA1/2 have been reported in malignant peripheral nerve sheath tumors (MPNSTs), MPNST cells could be effectively targeted with a PARP inhibitor to drive cells to synthetic lethality due to their complex karyotype and high level of inherent genomic instability...
2016: Cancer Biology & Therapy
https://www.readbyqxmd.com/read/26183824/poly-adp-ribose-polymerase-as-a-novel-regulator-of-17%C3%AE-estradiol-induced-cell-growth-through-a-control-of-the-estrogen-receptor-igf-1-receptor-pdzk1-axis
#10
Hogyoung Kim, Abdelmetalab Tarhuni, Zakaria Y Abd Elmageed, A Hamid Boulares
BACKGROUND: We and others have extensively investigated the role of PARP-1 in cell growth and demise in response to pathophysiological cues. Most of the clinical trials on PARP inhibitors are targeting primarily estrogen receptor (ER) negative cancers with BRCA-deficiency. It is surprising that the role of the enzyme has yet to be investigated in ER-mediated cell growth. It is noteworthy that ER is expressed in the majority of breast cancers. We recently showed that the scaffolding protein PDZK1 is critical for 17β-estradiol (E2)-induced growth of breast cancer cells...
2015: Journal of Translational Medicine
https://www.readbyqxmd.com/read/26180927/long-term-safety-and-anti-tumour-activity-of-olaparib-monotherapy-after-combination-with-carboplatin-and-paclitaxel-in-patients-with-advanced-breast-ovarian-or-fallopian-tube-cancer
#11
Ruud van der Noll, Serena Marchetti, Neeltje Steeghs, Jos H Beijnen, Marja W J Mergui-Roelvink, Emmy Harms, Harriet Rehorst, Gabe S Sonke, Jan H M Schellens
BACKGROUND: Olaparib (AZD2281), a PARP-1/2 inhibitor, has been extensively investigated in clinical trials. However, limited clinical data are available about its long-term safety and anti-tumour activity. METHODS: Patients had first participated in a phase I study of olaparib combined with carboplatin and/or paclitaxel. They continued with olaparib monotherapy in their best interest if they failed to tolerate the combination due to the treatment-related adverse events (TRAEs)...
July 28, 2015: British Journal of Cancer
https://www.readbyqxmd.com/read/26124641/combination-of-erlotinib-and-a-parp-inhibitor-inhibits-growth-of-a2780-tumor-xenografts-due-to-increased-autophagy
#12
Hongying Sui, Caixia Shi, Zhipeng Yan, Hucheng Li
BACKGROUND: Ovarian cancer is the leading cause of death in women with gynecological malignancy worldwide. Despite multiple new approaches to treatment, relapse remains almost inevitable in patients with advanced disease. The poor outcome of advanced ovarian cancer treated with conventional therapy stimulated the search for new strategies to improve therapeutic efficacy. Although epidermal growth factor receptor (EGFR) and poly(ADP-ribose) polymerase (PARP) inhibitors have known activity in advanced ovarian cancer, the effect of combined therapy against EGFR and PARP in this population has not been reported...
2015: Drug Design, Development and Therapy
https://www.readbyqxmd.com/read/25975349/the-parp-inhibitor-azd2281-olaparib-induces-autophagy-mitophagy-in-brca1-and-brca2-mutant-breast-cancer-cells
#13
Banu Arun, Ugur Akar, Angelica M Gutierrez-Barrera, Gabriel N Hortobagyi, Bulent Ozpolat
PARP inhibitors are considered promising anticancer agents and currently being tested in clinical trials in hereditary breast cancer patients harboring mutations in BRCA1 and BRCA2 genes. In this study, we investigated the antiproliferative effects and mechanism of PARP inhibitors ABT-888 (Veliparib), BSI-201 (Iniparib) and AZD228 (Olaparib) in breast cancer cell lines with BRCA1 or BRCA2 mutations and 9 different BRCA wild-type cell lines with BRCA1 allelic loss. We found that AZD2281 was the most potent in the PARP inhibitors and induces significant growth inhibition (~95%) in BRCA1 mutant (HCC‑1937, MDA-MB-436, and SUM-149PT) and BRCA2 mutant (HCC‑1428) cell lines...
July 2015: International Journal of Oncology
https://www.readbyqxmd.com/read/25885900/annonaceous-acetogenin-mimic-aa005-induces-cancer-cell-death-via-apoptosis-inducing-factor-through-a-caspase-3-independent-mechanism
#14
Bing Han, Tong-Dan Wang, Shao-Ming Shen, Yun Yu, Chan Mao, Zhu-Jun Yao, Li-Shun Wang
BACKGROUND: Annonaceous acetogenins are a family of natural products with antitumor activities. Annonaceous acetogenin mimic AA005 reportedly inhibits mammalian mitochondrial NADH-ubiquinone reductase (Complex I) and induces gastric cancer cell death. However, the mechanisms underlying its cell-death-inducing activity are unclear. METHODS: We used SW620 colorectal adenocarcinoma cells to study AA005 cytotoxic activity. Cell deaths were determined by Trypan blue assay and flow cytometry, and related proteins were characterized by western blot...
2015: BMC Cancer
https://www.readbyqxmd.com/read/25784115/annonaceous-acetogenin-mimic-aa005-induces-cancer-cell-death-via-apoptosis-inducing-factor-through-a-caspase-3-independent-mechanism
#15
Bing Han, Tong-Dan Wang, Shao-Ming Shen, Yun Yu, Chan Mao, Zhu-Jun Yao, Li-Shun Wang
BACKGROUND: Annonaceous acetogenins are a family of natural products with antitumor activities. Annonaceous acetogenin mimic AA005 reportedly inhibits mammalian mitochondrial NADH-ubiquinone reductase (Complex I) and induces gastric cancer cell death. However, the mechanisms underlying its cell-death-inducing activity are unclear. METHODS: We used SW620 colorectal adenocarcinoma cells to study AA005 cytotoxic activity. Cell deaths were determined by Trypan blue assay and flow cytometry, and related proteins were characterized by western blot...
2015: BMC Cancer
https://www.readbyqxmd.com/read/25757679/olaparib-an-oral-parp-1-and-parp-2-inhibitor-with-promising-activity-in-ovarian-cancer
#16
REVIEW
Camille C Gunderson, Kathleen N Moore
Olaparib (Lynparza™; AZD2281) is a potent PARP-1 and PARP-2 inhibitor with biologic activity in ovarian cancer as well as other solid tumors. It has been tested in Phase I and II trials and has single-agent activity in both germline BRCA mutated and sporadic ovarian cancer. Phase III trials assessing the efficacy of olaparib in the maintenance setting following first line and platinum-sensitive recurrence are underway for patients with a germline BRCA mutation, given the inherent molecular compatibility with the drug's mechanism of action...
2015: Future Oncology
https://www.readbyqxmd.com/read/25604309/novel-poly-adp-ribose-polymerase-inhibitor-azd2281-enhances-radiosensitivity-of-both-normoxic-and-hypoxic-esophageal-squamous-cancer-cells
#17
L Zhan, Q Qin, J Lu, J Liu, H Zhu, X Yang, C Zhang, L Xu, Z Liu, J Cai, J Ma, S Dai, G Tao, H Cheng, X Sun
Radiotherapy plays an important role in the treatment of esophageal squamous cell carcinoma (ESCC). However, the outcome of radiotherapy in ESCC remains unsatisfactory because esophageal squamous cancer cells, particularly those under hypoxic condition, exhibit radioresistance. The aim of this study was to determine whether or not AZD2281, a potent poly (ADP-ribose) polymerase (PARP) inhibitor, could enhance the radiation sensitivity of two ESCC cell lines, namely ECA109 and TE13. The radiosensitizing effect of AZD2281 was evaluated on the basis of cell death, clonogenic survival and tumor xenograft progression...
April 2016: Diseases of the Esophagus: Official Journal of the International Society for Diseases of the Esophagus
https://www.readbyqxmd.com/read/25120693/xrcc2-rs3218536-polymorphism-decreases-the-sensitivity-of-colorectal-cancer-cells-to-poly-adp-ribose-polymerase-1-inhibitor
#18
Kaiwu Xu, Xinming Song, Zhihui Chen, Changjiang Qin, Yulong He
Single nucleotide polymorphisms (SNPs) are associated with the development of certain types of cancer. The present study aimed to investigate the association between X-ray repair complementing defective repair in Chinese hamster cells 2 (XRCC2) SNPs and colorectal cancer (CRC) cell sensitivity to the poly(ADP-ribose) polymerase (PARP) 1 inhibitor olaparib (AZD2281). SNaPshot(®) analysis of XRCC2 SNPs was performed in five CRC cell lines. The AZD2281-sensitivities of the CRC cells were also analyzed using MTT assays...
September 2014: Oncology Letters
https://www.readbyqxmd.com/read/24965603/quantitative-measurement-of-alterations-in-dna-damage-repair-ddr-pathways-using-single-cell-network-profiling-scnp
#19
David B Rosen, Ling Y Leung, Brent Louie, James A Cordeiro, Andrew Conroy, Iuliana Shapira, Scott Z Fields, Alessandra Cesano, Rachael E Hawtin
BACKGROUND: Homologous recombination repair (HRR) pathway deficiencies have significant implications for cancer predisposition and treatment strategies. Improved quantitative methods for functionally characterizing these deficiencies are required to accurately identify patients at risk of developing cancer and to identify mechanisms of drug resistance or sensitivity. METHODS: Flow cytometry-based single cell network profiling (SCNP) was used to measure drug-induced activation of DNA damage response (DDR) proteins in cell lines with defined HRR pathway mutations (including ATM-/-, ATM+/-, BRCA1+/-, BRCA2-/-) and in primary acute myeloid leukemia (AML) samples...
June 25, 2014: Journal of Translational Medicine
https://www.readbyqxmd.com/read/24675890/doxorubicin-enhances-snail-lsd1-mediated-pten-suppression-in-a-parp1-dependent-manner
#20
Yiwei Lin, Tiebang Kang, Binhua P Zhou
The transcription factor Snail not only functions as a master regulator of epithelial-mesenchymal transition (EMT), but also mediates cell proliferation and survival. While previous studies have showed that Snail protects tumor cells from apoptosis through transcriptional repression of PTEN, the specific mechanism remains unclear. In this study, we demonstrated that Snail cooperates with LSD1 to repress PTEN in a PARP1-dependent manner. Upon doxorubicin treatment, Snail becomes tightly associated with PARP1 through its pADPr-binding motif and is subject to poly(ADP-ribosyl)ation...
2014: Cell Cycle
keyword
keyword
40657
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"